<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nierengarten, Mary Beth</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Mease, Philip J.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Efficacy of Secukinumab Sustained over Time for Treatment of Active PsA</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-12-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">14-15</style></pages><abstract><style  face="normal" font="default" size="100%">This article presents the results of the Efficacy at 24 Weeks and Long-Term Safety, Tolerability, and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA) study [FUTURE 1; NCT01392326]. FUTURE 1 is a multicenter, placebo-controlled phase 3 study in which 606 patients with PsA received an intravenous loading dose of secukinumab at 10 mg/kg every 2 weeks for the first 4 weeks, followed by subcutaneous doses of 75 mg (n=202) or 150 mg (n=202) monthly, compared with placebo (n=202).</style></abstract><number><style face="normal" font="default" size="100%">51</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>